Search

Displaying results 5381 - 5390 of 10000 in total
  1. Drug

    ABBV-514

    go.drugbank.com/drugs/DB17586
    Investigational

    ABBV-514 is in development for the treatment of non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) as a single agent and in combination with a PD-1 inhibitor.[L45464]

  2. Drug

    Metisazone

    go.drugbank.com/drugs/DB13641
    Experimental

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use
  3. Drug

    Talampicillin

    go.drugbank.com/drugs/DB13814
    Experimental

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  4. Drug

    Anethole

    go.drugbank.com/drugs/DB15916
    ApprovedWithdrawn

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    XL228

    go.drugbank.com/drugs/DB05184
    Investigational

    XL228 is a novel anticancer compound designed to inhibit the insulin-like growth factor type-1 receptor (IGF1R), Src and Abl tyrosine kinases – targets that play crucial roles in cancer cell proliferation

  6. Drug

    Vociprotafib

    go.drugbank.com/drugs/DB21559
    Investigational

    Vociprotafib has a monoisotopic molecular weight of 450.16 Da. … Vociprotafib is under investigation in clinical trial NCT05054725 (Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies).

  7. Drug

    Pentaerithrityl

    go.drugbank.com/drugs/DB13526
    Investigational

    Categories: Drugs for Constipation
  8. Drug

    Carrimycin

    go.drugbank.com/drugs/DB16476
    Investigational

    Categories: Experimental Unapproved Treatments for COVID-19
  9. Drug

    Col-118

    go.drugbank.com/drugs/DB05778
    Investigational

    COL-118, a topical compound based on the SansRosa technology, for the treatment of redness associated with rosacea and other skin disorders. … Col-118 is a unique formulation and presentation of Brimonidine, which is a selective alpha-2 adrenergic receptor agonist.

  10. Drug

    Halofuginone

    go.drugbank.com/drugs/DB04866
    InvestigationalVet approved

    Halofuginone is a low molecular weight quinazolinone alkaloid, and a potent inhibitor of collagen alpha1(I) and matrix metalloproteinase 2 (MMP-2) gene expression. … Collgard Biopharmaceuticals is developing halofuginone for the treatment of scleroderma and received orphan drug designation from the U.S. Food and Drug Administration in March, 2000.